Skip to content
HowShorted

Anika Therapeutics Inc. short interest in 2018

In 2018, Anika Therapeutics Inc.'s disclosed short interest ran from 8.87% of shares outstanding on 12 Jan 2018 to 16.68% on 31 Dec 2018, a change of +7.81 percentage points. The year's high was 17.43% on 15 Aug 2018 and its low 7.46% on 28 Feb 2018, averaging 13.35% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 32.58 days on 14 Sep 2018. Full history: Anika Therapeutics Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Anika Therapeutics Inc. in 2018

2018 in figures

Start of year
8.87% (12 Jan 2018)
End of year
16.68% (31 Dec 2018)
Change
+7.81 pp
High
17.43% (15 Aug 2018)
Low
7.46% (28 Feb 2018)
Average
13.35%
Highest days to cover
32.58 (14 Sep 2018)
SEC filings marked
8

Every report in 2018

Anika Therapeutics Inc. short interest in 2018
SettlementShort interestDays to coverFilings since previous
12 Jan 20188.87%22.82
31 Jan 20188.57%16.48
15 Feb 20188.08%10.08
28 Feb 20187.46%8.76results (8-K), 10-K filed
15 Mar 20187.72%13.28
29 Mar 20187.73%11.29
13 Apr 20187.94%11.15
30 Apr 20188.17%8.53
15 May 20189.71%6.05results (8-K), 10-Q filed
31 May 201814.64%9.88
15 Jun 201814.88%12.83
29 Jun 201816.97%3.59
13 Jul 201817.19%20.02
31 Jul 201817.29%8.97results (8-K), 10-Q filed
15 Aug 201817.43%25.66
31 Aug 201817.21%30.55
14 Sep 201817.07%32.58
28 Sep 201816.95%24.09
15 Oct 201815.79%28.62
31 Oct 201815.65%21.25results (8-K), 10-Q filed
15 Nov 201816.09%22.71
30 Nov 201816.27%28.38
14 Dec 201816.16%18.08
31 Dec 201816.68%13.20

See also: Anika Therapeutics Inc.'s full history · most shorted US stocks of 2018 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.